Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Ezra E.W. Cohen(Moores Cancer Center), Makoto Tahara(National Cancer Center Hospital East), József Lövey(Országos Reumatológiai és Fizioterápiás Intézet), J. Chamois(Centre Hospitalier privé Saint Grégoire), Jin‐Ching Lin(Changhua Christian Hospital), Lara Dunn(Memorial Sloan Kettering Cancer Center), Dmitri Pavlov(Pfizer (United States)), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Amanda Psyrri(National and Kapodistrian University of Athens), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Jean Bourhis(University of Lausanne), Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Peter Mu‐Hsin Chang(National Yang Ming Chiao Tung University), Chaosu Hu(Ministry of Agriculture and Rural Affairs), Antonio Rueda(Instituto de Investigación Biomédica de Málaga), Mohammad Razaq(University of Oklahoma Health Sciences Center), Maria Margarida Teixeira(Instituto Português de Oncologia de Coimbra Francisco Gentil), Steven De Beukelaer(Pfizer (Switzerland)), Holger Thurm(Pfizer (United States))
Cited by 618
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k